AntriaBio, Inc. announced the appointment of Dr. Robert B. Bhisitkul, M.D., Ph.D. to its Scientific Advisory Board. The addition of Dr. Bhisitkul to the Scientific Advisory Board follows the company’s recent in-licensing of an oral plasma kallikrein inhibitor (PKI) portfolio announced on August 7th. As such, AntriaBio is bolstering its leadership team and allocating resources to develop treatments for kallikrein-mediated diseases, diabetic macular edema (DME) and hereditary angioedema (HAE). Dr. Bhisitkul is a Professor of Clinical Ophthalmology and retinal specialist at the University of California, San Francisco School of Medicine’s Department of Ophthalmology.